Identity & Authority: AbbVie Inc. and Genentech (VENCLEXTA) – Signal Evidence & AI Readability

{
    "@context": "http://schema.org",
    "@type": "MedicalWebPage",
    "audience": "https://health-lifesci.schema.org/Patient",
    "specialty": "http://health-lifesci.schema.org/Oncologic",
    "headline": "VENCLEXTA® (venetoclax tablets): CLL/SLL and AML Treatment",
    "description": "Discover VENCLEXTA: An oral therapy to help you fight certain blood cancers. See full Prescribing and Safety information.",
    "url": "https://www.venclexta.com",
    "mainContentOfPage": [
        "Uses",
        "Important Safety Information"
    ],
    "potentialaction": [
        {
            "@type": "ViewAction",
            "name": "Previously Untreated CLL/SLL",
            "description": "Choose a future free from continuous CLL treatment. Discover chemo-free VENCLEXTA.",
            "url": "https://www.venclexta.com/previously-untreated-cll"
        },
        {
            "@type": "ViewAction",
            "name": "Previously Treated CLL/SLL",
            "description": "Choose a CLL treatment designed to be different. Discover chemo-free VENCLEXTA",
            "url": "https://www.venclexta.com/previously-treated-cll"
        },
        {
            "@type": "ViewAction",
            "name": "Acute Myeloid Leukemia (AML)",
            "description": "Discover VENCLEXTA as a treatment for acute myeloid leukemia (AML).",
            "url": "https://www.venclexta.com/aml"
        },
        {
            "@type": "ReadAction",
            "name": "Uses",
            "description": [
                "To treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).",
                "in combination with azacitidine, or decitabine, or locytarabine to treat adults with newly-diagnosed acute myeloid leukemia (AML) who: are 75 years of age or older, or have other medical conditions that prevent the use of stchemotherapy.",
                "VENCLEXTA was approved based on response rates. Continued approval for this use may depend on the results of an ongoing study to find out how VENCLEXTAover a longer period of time.",
                "It is not known if VENCLEXTA is safe and effective in children."
            ]
        }
    ],
    "about": {
        "@type": "MedicalCondition",
        "name": [
            "chronic lymphocytic leukemia (CLL)",
            "small lymphocytic lymphoma (SLL)",
            "acute myeloid leukemia (AML)"
        ],
        "drug": {
            "@type": "Drug",
            "name": "Venclexta",
            "nonProprietaryName": "venetoclax",
            "dosageForm": "tablets",
            "administrationRoute": "oral",
            "prescribingInfo": "https://www.rxabbvie.com/pdf/venclexta.pdf"
        }
    },
    "mainEntity": [
        {
            "@type": "Question",
            "text": "What is the most important information I should know about VENCLEXTA?",
            "acceptedAnswer": {
                "@type": "Answer",
                "text": "VENCLEXTA can cause serious side effects, including:Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and may lead to death. Your healthcare provider will do tests to check your risk of getting TLS before you start taking VENCLEXTA. You will receive other medicines before starting and during treatment with VENCLEXTA to help reduce your risk of TLS. You may also need to receive intravenous (IV) fluids into your vein. Your healthcare provider will do blood tests to check for TLS when you first start treatment and during treatment with VENCLEXTA. It is important to keep your appointments for blood tests. Tell your healthcare provider right away if you have any symptoms of TLS during treatment with VENCLEXTA, including fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness, or muscle or joint pain. Drink plenty of water during treatment with VENCLEXTA to help reduce your risk of getting TLS. Drink 6 to 8 glasses (about 56 ounces total) of water each day, starting 2 days before your first dose, on the day of your first dose of VENCLEXTA, and each time your dose is increased. Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA if you have side effects."
            }
        },
        {
            "@type": "Question",
            "text": "Who should not take VENCLEXTA?",
            "acceptedAnswer": {
                "@type": "Answer",
                "text": "Certain medicines must not be taken when you first start taking VENCLEXTA and while your dose is being slowly increased because of the risk of increased TLS. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VENCLEXTA and other medicines may affect each other causing serious side effects. Do not start new medicines during treatment with VENCLEXTA without first talking with your healthcare provider. Before taking VENCLEXTA, tell your healthcare provider about all of your medical conditions, including if you: have kidney or liver problems, have problems with your body salts or electrolytes, such as potassium, phosphorus, or calcium, have a history of high uric acid levels in your blood or gout, are scheduled to receive a vaccine. You should not receive a live vaccine before, during, or after treatment with VENCLEXTA, until your healthcare provider tells you it is okay. If you are not sure about the type of immunization or vaccine, ask your healthcare provider. These vaccines may not be safe or may not work as well during treatment with VENCLEXTA, are pregnant or plan to become pregnant. VENCLEXTA may harm your unborn baby. If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with VENCLEXTA, and you should use effective birth control during treatment and for at least 30 days after the last dose of VENCLEXTA. If you become pregnant or think you are pregnant, tell your healthcare provider right away, are breastfeeding or plan to breastfeed. It is not known if VENCLEXTA passes into your breast milk. Do not breastfeed during treatment with VENCLEXTA."
            }
        },
        {
            "@type": "Question",
            "text": "What should I avoid while taking VENCLEXTA?",
            "acceptedAnswer": {
                "@type": "Answer",
                "text": "You should not drink grapefruit juice or eat grapefruit, Seville oranges (often used in marmalades), or starfruit while you are taking VENCLEXTA. These products may increase the amount of VENCLEXTA in your blood."
            }
        },
        {
            "@type": "Question",
            "text": "What are the possible side effects of VENCLEXTA?",
            "acceptedAnswer": {
                "@type": "Answer",
                "text": "VENCLEXTA can cause serious side effects, including:Low white blood cell counts (neutropenia). Low white blood cell counts are common with VENCLEXTA, but can also be severe. Your healthcare provider will do blood tests to check your blood counts during treatment with VENCLEXTA. Infections. Death and serious infections such as pneumonia and blood infection (sepsis) have happened during treatment with VENCLEXTA. Your healthcare provider will closely monitor and treat you right away if you have a fever or any signs of infection during treatment with VENCLEXTA.Tell your healthcare provider right away if you have a fever or any signs of an infection during treatment with VENCLEXTA. The most common side effects of VENCLEXTA when used in combination with obinutuzumab or rituximab or alone in people with CLL or SLL include low white blood cell counts; low platelet counts; low red blood cell counts; diarrhea; nausea; upper respiratory tract infection; cough; muscle and joint pain; tiredness; and swelling of your arms, legs, hands, and feet. The most common side effects of VENCLEXTA in combination with azacitidine or decitabine or low-dose cytarabine in people with AML include low white blood cell counts; nausea; diarrhea; low platelet counts; constipation; fever with low white blood cell counts; low red blood cell counts; infection in blood; rash; dizziness; low blood pressure; fever; swelling of your arms, legs, hands, and feet; vomiting; tiredness; shortness of breath; bleeding; infection in lung; stomach (abdominal) pain; pain in muscles or back; cough; and sore throat. VENCLEXTA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility. These are not all the possible side effects of VENCLEXTA."
            }
        }
    ],
    "creator": {
        "@type": "Corporation",
        "name": [
            "AbbVie Inc.",
            "Genentech"
        ]
    },
    "image": {
        "@type": "ImageObject",
        "name": "VENCLEXTA logo",
        "contentUrl": "https://www.venclexta.com/content/dam/venclexta/images/logo-venclexta.png"
    }
}

{
    "@context": "http://schema.org",
    "@type": "MedicalWebPage",
    "audience": "https://health-lifesci.schema.org/Patient",
    "specialty": "http://health-lifesci.schema.org/Oncologic",
    "headline": "VENCLEXTA® (venetoclax tablets) for Untreated CLL/SLL Patients",
    "description": "Discover chemo-free VENCLEXTA® (venetoclax tablets) and a future free from continuous chronic lymphocytic leukemia treatment. See full Prescribing and Safety info.",
    "url": "https://www.venclexta.com/previously-untreated-cll",
    "potentialAction": [
        {
            "@type": "ViewAction",
            "name": "Learn how VENCLEXTA can help",
            "url": "https://www.venclexta.com/previously-untreated-cll/why-venclexta/how-it-may-help"
        },
        {
            "@type": "ViewAction",
            "name": "Explore Financial & Treatment Support",
            "url": "https://www.venclexta.com/previously-untreated-cll/resources-and-support/financial-and-treatment-support"
        },
        {
            "@type": "ViewAction",
            "name": "Get Helpful Resources & Materials",
            "url": "https://www.venclexta.com/previously-untreated-cll/resources-and-support/helpful-resources-and-materials"
        },
        {
            "@type": "ViewAction",
            "name": "Why VENCLEXTA is different",
            "url": "https://www.venclexta.com/previously-untreated-cll/why-venclexta/how-its-different"
        },
        {
            "@type": "ViewAction",
            "name": "Get information about taking VENCLEXTA",
            "url": "https://www.venclexta.com/previously-untreated-cll/taking-venclexta/dosing-instructions"
        },
        {
            "@type": "ViewAction",
            "name": "Learn how VENCLEXTA can help",
            "url": "https://www.venclexta.com/previously-untreated-cll/why-venclexta/how-it-may-help"
        },
        {
            "@type": "ViewAction",
            "name": "REAL VENCLEXTA STORIES",
            "description": "See how John completed his VENCLEXTA treatment in 12 months",
            "url": "https://www.venclexta.com/previously-untreated-cll/why-venclexta/cll-stories"
        },
        {
            "@type": "ReadAction",
            "Name": "Use",
            "Description": "VENCLEXTA is a prescription medicine used to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is not known if VENCLEXTA is safe and effective in children."
        }
    ],
    "about": {
        "@type": "MedicalCondition",
        "name": [
            "chronic lymphocytic leukemia(CLL)",
            "small lymphocytic lymphoma(SLL)"
        ],
        "drug": {
            "@type": "Drug",
            "name": "Venclexta",
            "nonProprietaryName": "venetoclax",
            "dosageForm": "tablets",
            "administrationRoute": "oral",
            "prescribingInfo": "https://www.rxabbvie.com/pdf/venclexta.pdf"
        }
    }
}

{
    "@context": "http://schema.org",
    "@type": "MedicalWebPage",
    "audience": "https://health-lifesci.schema.org/Patient",
    "specialty": "http://health-lifesci.schema.org/Oncologic",
    "headline": "VENCLEXTA® for Previously Treated CLL/SLL Patients",
    "description": "Discover chemo-free VENCLEXTA® (venetoclax tablets), a treatment for relapsed/refractory CLL/SLL designed to be different. See full Prescribing and Safety info.",
    "url": "https://www.venclexta.com/previously-treated-cll",
    "potentialAction": [
        {
            "@type": "ViewAction",
            "name": "Learn how VENCLEXTA can help",
            "url": "https://www.venclexta.com/previously-treated-cll/why-venclexta/how-it-may-help"
        },
        {
            "@type": "ViewAction",
            "name": "Explore Financial & Treatment Support",
            "url": "https://www.venclexta.com/previously-treated-cll/resources-and-support/financial-and-treatment-support"
        },
        {
            "@type": "ViewAction",
            "name": "Learn how VENCLEXTA works",
            "url": "https://www.venclexta.com/previously-treated-cll/why-venclexta/how-it-works"
        },
        {
            "@type": "ViewAction",
            "name": "Get Helpful Resources & Materials",
            "url": "https://www.venclexta.com/previously-treated-cll/resources-and-support/helpful-resources-and-materials"
        },
        {
            "@type": "ViewAction",
            "name": "Why VENCLEXTA is different",
            "url": "https://www.venclexta.com/previously-treated-cll/why-venclexta/how-its-different"
        },
        {
            "@type": "ViewAction",
            "name": "Get information about taking VENCLEXTA",
            "url": "https://www.venclexta.com/previously-treated-cll/taking-venclexta/dosing-instructions"
        },
        {
            "@type": "ViewAction",
            "name": "Find out how VENCLEXTA can help",
            "url": "https://www.venclexta.com/previously-treated-cll/why-venclexta/how-it-may-help"
        },
        {
            "@type": "ViewAction",
            "name": "REAL VENCLEXTA STORIES",
            "description": "See Danise share her journey with CLL and VENCLEXTA treatment",
            "url": "https://www.venclexta.com/previously-treated-cll/why-venclexta/cll-stories"
        },
        {
            "@type": "ReadAction",
            "Name": "Use",
            "Description": "VENCLEXTA is a prescription medicine used to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is not known if VENCLEXTA is safe and effective in children."
        }
    ],
    "about": {
        "@type": "MedicalCondition",
        "name": [
            "chronic lymphocytic leukemia(CLL)",
            "small lymphocytic lymphoma(SLL)"
        ],
        "drug": {
            "@type": "Drug",
            "name": "Venclexta",
            "nonProprietaryName": "venetoclax",
            "dosageForm": "tablets",
            "administrationRoute": "oral",
            "prescribingInfo": "https://www.rxabbvie.com/pdf/venclexta.pdf"
        }
    }
}